Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
The Oncologist|December 24, 2025
Baseline geriatric 8 (G8) screening tool predicts overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitorsChristopher H Rhee, Subir Goyal, Yuan Liu, et al.
Frontiers in Endocrinology|April 8, 2022
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer ImmunotherapyT Anders Olsen, Tony Zibo Zhuang, Sarah Caulfield, et al.
Frontiers in Oncology|December 19, 2022
Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah's witness: A case reportTony Zibo Zhuang, Lara Harik, Seth Force, et al.
Cancer|August 9, 2025
Optimizing treatment for metastatic castration-resistant prostate cancer: Food and Drug Administration-approved therapies, emerging strategies, and biomarker-driven approachesFaisal Saeed, Jacob E Berchuck, Mehmet Asim Bilen, et al.
The Oncologist|April 24, 2022
Blood-Based Next-Generation Sequencing in Adrenocortical CarcinomaBassel Nazha, Tony Z Zhuang, Hiba I Dada, et al.
American Journal of Clinical Pathology|December 20, 2024
Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypesKatherine B Case, Dylan J Martini, Melad N Dababneh, et al.
Cancer|September 9, 2020
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancerBassel Nazha, Subir Goyal, Zhengjia Chen, et al.
The Oncologist|June 7, 2021
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment OptionsKatherine Emilie Rhoades Smith, Jacqueline Theresa Brown, Limeng Wan, et al.
Urologic Oncology|April 25, 2022
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancerAgreen Hadadi, Katherine Er Smith, Limeng Wan, et al.
Cancer Medicine|April 14, 2026
Phase II Trial of Opaganib Addition in Metastatic Castration-Resistant Prostate Cancer After Disease Progression on Abiraterone or EnzalutamideJacqueline T Brown, Bassel Nazha, Anna C Ferreira, et al.
Pageof 6